Rznomics
Price chart
- MA5
- MA20
- MA60
Adjusted prices rescale past bars with coefficients taken from the base prices the exchange itself published, correcting for corporate actions such as stock splits and reverse splits. Cash dividends are not reflected, and the risk measures on this page never use these adjusted figures.
Each day's close multiplied by the listed share count of this share class alone, sampled weekly. It is the figure for this issue only, not a combined total across common and preferred shares.
Overview
Summary
Rznomics is a biotechnology company established on August 29, 2017. The company is listed on the KOSDAQ market.
The company develops gene therapies using RNA substitution enzyme and self-circularizing RNA platforms. It focuses on discovering treatments for cancer, genetic diseases, and degenerative diseases. The company pursues commercialization through joint research and technology transfers with domestic and international pharmaceutical partners.
Business overview as filed
당사는 RNA 편집·교정 분야의 글로벌 선도기업으로서, RNA 치환효소 플랫폼을 기반으로 한 유전자치료제와 원형 RNA 플랫폼을 보유하고 있습니다. 당사의 기술은 RNA 치환효소 기반 신규 유전자치료제 발굴·최적화와 RNA 치환효소 기반 원형 RNA 신규 물질 발굴·최적화를 자체적으로 수행할 수 있는 기술을 포함하는 RNA 플랫폼입니다. 이를 바탕으로 표적 유전자 RNA를 특이적으로 표적하여 유전자 발현을 낮춤과 동시에, 치료용 유전자로의 편집·교정을 통한 치료 효과를 발휘할 수 있는 항암, 유전질환 및 퇴행성질환 유전자치료제를 발굴할 수 있으며, 자가환형화 RNA 구조체를 이용해 기존 선형 RNA를 대체할 수 있는 치료제, 백신 등의 신규 물질을 발굴·제작할 수 있는 독자적인 기술을 보유하고 있습니다.당사에서 발굴한 유전자치료제 및 원형 RNA는 그 물질 자체로 임상개발 및 기술이전 등의 사업화가 가능할 뿐 아니라, RNA 플랫폼 기술 기반 치료제에 대한 지적재산권도 사업화가 가능합니다. 특히 당사의 RNA 치환효소 기반 유전자치료제는 기존 약물로 표적하기 어려웠던 RNA를 표적할 수 있고, 다양한 돌연변이에 대해 하나의 치료제로 대응할 수 있어 기술사업화에 유리합니다. 특히, 표적 유전자의 편집·교정을 통해 부작용은 최소화하며, 유전자치료제의 치료효율이 높다는 점에서 차별화된 기술입니다. 자가환형화 RNA 기술로 생성된 원형 RNA는 기존 PIE 기술 기반의 원형 RNA의 한계점을 극복한 새로운 기술로써, 해당 원천기술에 대한 첨단바이오의약품 및 백신 개발기업과 다양한 사업 협력을 기대하고 있습니다.당사의 RNA 플랫폼을 통해 생산된 물질 및 지적재산권을 활용해 다양한 신약 파이프라인을 자체적으로 혹은 파트너사와 공동으로 연구개발하고 있으며, 동시에 해당 플랫폼 바탕의 비즈니스 활동을 통해 기술이전을 통한 매출 실현에 노력하고 있습니다.
Company overview
가. 연결대상 종속회사 개황
1-1. 연결대상회사의 변동내용
나. 회사의 법적, 상업적 명칭
당사의 명칭은 "알지노믹스 주식회사"라고 표기합니다. 또한 영문으로는 Rznomics Inc.라 표기합니다.
다. 설립일자 및 존속기간
당사는 유전자치료제 연구 및 개발을 목적으로 2017년 8월 29일에 설립되었습니다.
라. 본사의 주소, 전화번호, 홈페이지 주소
마. 중소기업 등 해당 여부
중소기업확인서(2025.03.28).jpeg 중소기업확인서(2025.03.28)
벤처기업확인서(2025.06.18).jpeg 벤처기업확인서(2025.06.18)
바. 주요 사업의 내용
당사는 2017년 8월 29일에 설립되었으며, RNA 치환효소 플랫폼 및 자가환형화 RNA 플랫폼 기술 기반으로 유전자치료제를 개발하고 기술이전 등을 통한 사업화를 비즈니스 모델로 하는 바이오 신약 연구ㆍ개발 전문기업입니다. 당사는 항암 및 난치성 질환 바이오 신약개발을 목표로, 인체질환 치료제를 연구ㆍ개발하고 국내외 제약기업 등 파트너십을 통해 공동연구개발 및 기술이전을 추진하고 있습니다.
사. 회사의 주권상장(또는 등록ㆍ지정) 및 특례상장에 관한 사항
Transcribed verbatim from the sentences the filer wrote in the fiscal 2025 business report (received 2026.03.23), tables and figures omitted.
- The summary is written separately from the filed text and is not the filer's wording, so it may phrase things differently from or omit parts of the original, which is shown alongside for checking.
- The company introduction reproduces the sentences the filer wrote in its business report, with tables, figures and the sentences that point to other sections of the report omitted, and the accuracy of their content has not been separately verified.
The conditions for computing a value are not met over this window, which happens when the listing is short, turnover is thin, or halts are frequent.
Characteristic line
No window of this issue can carry a characteristic line yet.
Each point is one period's index excess return and issue excess return, and the line is the regression fitted to those points. The risk-free rate is the certificate of deposit rate.
- Beta summarizes by regression how far the issue's return moved together with the KOSPI200 or KOSDAQ150 index return, and the index is only a stand-in for the whole market.
- The intercept is the average excess return the index does not explain, and when the interval shown beside it contains zero it cannot be told apart from zero.
- Beta and the intercept are computed from the sample of the chosen window and frequency and are not values for the period ahead.
- At the daily frequency a beta corrected for differences in trading times is shown alongside, and the gap between the two shows how much later than the index the issue's trades are reflected.
Financials
| 2022 | 2023 | 2024 | 2025 | TTM | |
|---|---|---|---|---|---|
| RevenueKRW 100M | 0 | 1 | 0 | — | — |
| Revenue growth% | — | — | -100.00 | — | — |
| Operating incomeKRW 100M | -192 | -155 | -129 | -146 | -284 |
| Net incomeKRW 100M | -315 | -136 | -189 | -1,038 | -276 |
| Attributable to owners | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Attributable to minorities | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Operating margin% | — | -10,808.72 | — | — | — |
| Net margin% | — | -9,469.95 | — | — | — |
| ROE | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| ROA% | -88.99 | -67.30 | -66.97 | -165.21 | -53.55 |
| Debt ratio% | -156.61 | -127.04 | -130.19 | 6.72 | 10.62 |
| Current ratio% | 32.63 | 17.14 | 20.39 | 1,829.12 | 967.77 |
| Quick ratio | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Reserve ratio% | -3,983.68 | -4,771.65 | -5,881.20 | 678.40 | 197.08 |
| Free cash flowKRW 100M | -151 | -148 | -115 | — | — |
| FCF margin% | — | -10,330.41 | — | — | — |
| Capex to revenue% | — | 325.67 | — | — | — |
| EPSKRW | — | — | — | -14,183 | — |
| PER | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| BPS | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| PBR | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
| Dividend per share | Not applicable | Not applicable | Not applicable | Not applicable | Not applicable |
Separate basis
Profit flowKRW 100M
This fiscal year shows a loss at gross profit, operating income, profit before tax or net income, so it is left to the table rather than drawn as a flow.
This diagram traces where revenue goes at each step on its way to net income, using the filed amounts as they are. The non-operating result is taken as the difference between profit before tax and operating income and is shown as income or expense by its sign, and whatever a step's items leave unexplained is shown separately as other.
Revenue compositionKRW 100M
Cash flow by activityKRW 100M
Balance sheet compositionKRW 100M
Debt ratio%
The left bar splits assets into current and non-current and the right bar splits the financing of those assets into liabilities and equity, so the two bars stand at the same height.
Quarterly resultsKRW 100M
Each quarterly bar is that quarter's three months and is never mixed with an annual figure. The growth rate is computed only where the same quarter a year earlier is also shown here, and is left blank when the base was a loss.
Free cash flow breakdownKRW 100M
Free cash flow is cash from operating activities less spending on property, plant and equipment, and all three bars keep the sign as filed.
Owners' net margin%
Asset turnoverx
Financial leveragex
ROE%
ROE is the product of the owners' net margin, asset turnover and financial leverage. All three use period-end balances as denominators, and profit and equity are on the owners' basis, so the product matches the ROE in the table.
Financial statements
Balance sheet
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| 354 | 202 | 281 | 628 | |
| 315 | 160 | 245 | 549 | |
| Cash and cash equivalentsKRW 100M | 51 | 117 | 119 | 176 |
| Short-term financial instrumentsKRW 100M | 260 | 40 | 120 | 359 |
| InventoriesKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| Trade and other receivablesKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| 39 | 42 | 37 | 79 | |
| Property, plant and equipmentKRW 100M | 15 | 15 | 12 | 8 |
| Intangible assetsKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| 980 | 949 | 1,214 | 40 | |
| 965 | 933 | 1,200 | 30 | |
| Trade and other payablesKRW 100M | Not applicable | Not applicable | Not applicable | 25 |
| Current lease liabilitiesKRW 100M | 3 | 4 | 4 | 4 |
| 15 | 17 | 14 | 10 | |
| Non-current lease liabilitiesKRW 100M | 13 | 15 | 12 | — |
| -626 | -747 | -932 | 589 | |
| Not applicable | Not applicable | Not applicable | Not applicable | |
| Issued capitalKRW 100M | 17 | 17 | 17 | 70 |
| Capital surplusKRW 100M | 48 | 49 | 49 | 2,559 |
| Retained earningsKRW 100M | -723 | -859 | -1,048 | -2,086 |
| Non-controlling interestsKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| 기타채권As filed | 3 | 2 | 3 | 1 |
| 당기법인세자산As filed | 1 | 1 | 1 | 1 |
| 기타유동자산As filed | 0 | 0 | 2 | — |
| 계약자산As filed | — | — | — | 8 |
| 기타 비유동채권As filed | — | — | 6 | — |
| 무형자산As filed | 2 | 2 | 1 | 1 |
| 기타자산As filed | — | — | — | 3 |
| 장기기타채권As filed | 4 | 5 | — | — |
| 기타비유동자산As filed | 0 | 0 | 0 | — |
| 사용권자산As filed | 18 | 20 | 17 | 12 |
| 장기금융상품As filed | — | — | — | 50 |
| 기타자본조정As filed | 33 | 46 | 50 | — |
| 자본과부채총계As filed | 354 | 202 | 281 | 628 |
| 비유동기타채권As filed | — | — | — | 6 |
| 유동파생상품부채As filed | 766 | 719 | 687 | — |
| 기타채무As filed | 34 | 12 | 13 | — |
| 비유동기타자산As filed | — | — | — | 1 |
| 상환전환우선주부채As filed | 161 | 198 | 243 | — |
| 기타 유동부채As filed | 0 | 1 | 0 | — |
| 전환우선주부채As filed | — | — | 252 | — |
| 비유동충당부채As filed | 1 | 2 | 2 | 2 |
| 기타 비유동 부채As filed | 0 | 0 | 0 | — |
| 기타자본As filed | — | — | — | 46 |
| 기타부채As filed | — | — | — | 1 |
| 비유동기타부채As filed | — | — | — | 1 |
| 비유동리스부채As filed | — | — | — | 7 |
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| 0 | 1 | 0 | Not applicable | |
| Cost of salesKRW 100M | 0 | 0 | 0 | Not applicable |
| Gross profitKRW 100M | 0 | 1 | 0 | Not applicable |
| SG&A expensesKRW 100M | 192 | 157 | 129 | Not applicable |
| -192 | -155 | -129 | -146 | |
| Finance incomeKRW 100M | 7 | 57 | 98 | 6 |
| Finance costsKRW 100M | 129 | 39 | 157 | 887 |
| Other incomeKRW 100M | 1 | 2 | 1 | 2 |
| Other expensesKRW 100M | 2 | 1 | 2 | 3 |
| -315 | -136 | -189 | -1,028 | |
| Income tax expenseKRW 100M | 0 | 0 | 0 | 10 |
| -315 | -136 | -189 | -1,038 | |
| Attributable to ownersKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| Attributable to minoritiesKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| Basic earnings per shareKRW | Not applicable | Not applicable | Not applicable | -14,183 |
| Diluted earnings per shareKRW | Not applicable | Not applicable | Not applicable | -14,183 |
| -315 | -136 | -189 | -1,038 | |
| Other comprehensive incomeKRW 100M | 0 | 0 | 0 | Not applicable |
| 영업수익As filed | — | — | — | 79 |
| 영업비용As filed | — | — | — | 225 |
Cash flow statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Net incomefrom the income statement | -315 | -136 | -189 | -1,038 |
| Total adjustments to operating cash flowcomputed | 170 | -8 | 76 | 930 |
| -145 | -144 | -112 | -109 | |
| Interest receivedKRW 100M | 5 | 9 | 4 | 5 |
| Interest paidKRW 100M | 0 | Not applicable | Not applicable | Not applicable |
| Income taxes paidKRW 100M | 1 | 1 | -1 | Not applicable |
| -228 | 213 | -84 | -290 | |
| Purchase of property, plant and equipmentKRW 100M | 6 | 5 | 3 | Not applicable |
| Proceeds from sale of property, plant and equipmentKRW 100M | Not applicable | Not applicable | Not applicable | Not applicable |
| Purchase of intangible assetsKRW 100M | 1 | 0 | 0 | Not applicable |
| Cash flows from financing activitiesKRW 100M | 369 | -4 | 198 | 455 |
| Cash at beginning of periodKRW 100M | 55 | 51 | 117 | 119 |
| 51 | 117 | 119 | 176 | |
| Effect of exchange rate changesKRW 100M | -0 | -0 | 0 | -0 |
| Net change in cash and cash equivalentsKRW 100M | -4 | 66 | 2 | 57 |
| 리스부채의 상환As filed | -3 | -4 | -5 | -5 |
| 유상증자 및 주식선택권 행사As filed | — | — | — | 487 |
| 전환우선주의 발행As filed | — | — | 203 | — |
| 주식선택권행사로 인한 현금유입As filed | — | 0 | — | — |
| 상환전환우선주의 발행As filed | 372 | — | — | — |
| 단기금융상품의 감소(증가)As filed | -220 | 220 | -80 | — |
| 장기기타채권의 증가As filed | -2 | -2 | -0 | — |
| 주식발행비용 및 전환비용As filed | — | — | — | -27 |
| 단기금융상품의 증가As filed | — | — | — | -238 |
| 장기금융상품의 증가As filed | — | — | — | -50 |
| 영업으로부터 창출된 현금흐름As filed | -149 | -152 | -117 | -104 |
| 유형자산의 취득As filed | — | — | — | -0 |
| 환율변동효과 반영전 현금및현금성자산의 순증가(감소)As filed | -4 | 66 | 2 | — |
| 무형자산의 취득As filed | — | — | — | -1 |
| 법인세환급(납부)As filed | — | — | — | -11 |
| 환율변동효과전현금및현금성자산의 증가(감소)As filed | — | — | — | 57 |
In the latest fiscal year operations and investing consumed cash raised through financing activities.
A year whose own filing is absent is filled from the restated comparative in the following filing, and is marked as such. Operating indicators outside the statements, such as order backlogs, and audit opinions are not covered here, and per-share figures follow the filed values without retroactive adjustment for share splits.
Transcribed verbatim from the sentences the filer wrote in the fiscal {year} business report (received {date}), with tables, figures and cross-references to other sections omitted.
The newest annual filing shown was received on 2026.03.23.
Audit opinion
| Fiscal year | Opinion | Auditor | Fiscal year end |
|---|---|---|---|
| 2025 | 적정의견Term 9 | 삼일회계법인 | 2025-12-31 |
| 2024 | 적정의견Term 8 | 안진회계법인 | 2025-12-31 |
| 2023 | 적정의견Term 7 | 안진회계법인 | 2025-12-31 |
The auditor's name and the opinion are transcribed verbatim from the filed audit report, and the wording follows the filer. A fiscal year shown twice means the filing carried two entries that the source does not distinguish.
Korean audit opinions come in four kinds, where an unqualified opinion (적정) finds the statements fairly presented, a qualified opinion (한정) does so except for a stated matter, an adverse opinion (부적정) finds them not fairly presented, and a disclaimer of opinion (의견거절) means the auditor could not obtain enough evidence to form a view.